SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000947871-15-000713
Filing Date
2015-10-02
Accepted
2015-10-02 17:25:28
Documents
2
Group Members
ORBIMED CAPITAL GP V LLCSAMUEL D. ISALY

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss454757_sc13d.htm SC 13D 156257
2 JOINT FILING AGREEMENT ss454757_ex9901.htm EX-99.1 11708
  Complete submission text file 0000947871-15-000713.txt   169472
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address LEBERSTRASSE 20 VIENNA C4 1110
Business Address LEBERSTRASSE 20 VIENNA C4 1110 43 (0)1 740 93-0
Nabriva Therapeutics AG (Subject) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: C4 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-89113 | Film No.: 151141438
SIC: 2834 Pharmaceutical Preparations